AeroVironment Inc — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that AeroVironment Inc filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Apr 30, 2018 | $117.38M | Jun 27, 2018 |
| FY2018 | Jan 27, 2018 | $53.43M | Jun 27, 2018 |
| FY2018 | Oct 28, 2017 | $63.99M | Jun 27, 2018 |
| FY2018 | Jul 29, 2017 | $36.25M | Jun 27, 2018 |
| FY2018 | Apr 30, 2017 | $115.72M | Jun 27, 2018 |
| FY2018 | Jan 28, 2017 | $41.90M | Jun 27, 2018 |
| FY2018 | Oct 29, 2016 | $40.83M | Jun 27, 2018 |
| FY2018 | Jul 30, 2016 | $30.50M | Jun 27, 2018 |
| FY2017 | Apr 30, 2016 | $84.76M | Jun 28, 2017 |
| FY2017 | Jan 30, 2016 | $67.56M | Jun 28, 2017 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $318.64M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $283.93M | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | $173.51M | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | $141.24M | Jun 27, 2024 |
| FY2020 | Apr 30, 2021 | $59.66M | Jun 29, 2021 |
| FY2020 | Jan 30, 2021 | $28.64M | Jun 29, 2021 |
| FY2020 | Oct 31, 2020 | $40.85M | Jun 29, 2021 |
| FY2020 | Aug 1, 2020 | $35.41M | Jun 29, 2021 |
| FY2019 | Apr 30, 2020 | $53.17M | Jun 24, 2020 |
| FY2019 | Jan 31, 2020 | $23.50M | Jun 24, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $40.80M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $71.82M | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | ($178.66M) | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | ($9.89M) | Jun 27, 2024 |
| FY2023 | Apr 30, 2021 | $43.31M | Jun 28, 2023 |
| FY2022 | Apr 30, 2020 | $47.14M | Jun 29, 2022 |
| FY2020 | Apr 30, 2019 | $33.83M | Jun 29, 2021 |
| FY2019 | Apr 30, 2018 | $30.43M | Jun 24, 2020 |
| FY2019 | Apr 30, 2017 | $20.77M | Jun 26, 2019 |
| FY2018 | Apr 30, 2016 | $20.07M | Jun 27, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $100.73M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $97.69M | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | $64.26M | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | $54.69M | Jun 27, 2024 |
| FY2023 | Apr 30, 2021 | $53.76M | Jun 28, 2023 |
| FY2022 | Apr 30, 2020 | $46.48M | Jun 29, 2022 |
| FY2020 | Apr 30, 2019 | $34.23M | Jun 29, 2021 |
| FY2019 | Apr 30, 2018 | $26.43M | Jun 24, 2020 |
| FY2019 | Apr 30, 2017 | $28.47M | Jun 26, 2019 |
| FY2018 | Apr 30, 2016 | $35.04M | Jun 27, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $158.75M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $114.42M | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | $131.91M | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | $96.43M | Jun 27, 2024 |
| FY2023 | Apr 30, 2021 | $67.48M | Jun 28, 2023 |
| FY2022 | Apr 30, 2020 | $59.49M | Jun 29, 2022 |
| FY2020 | Apr 30, 2019 | $60.34M | Jun 29, 2021 |
| FY2019 | Apr 30, 2018 | $50.83M | Jun 24, 2020 |
| FY2019 | Apr 30, 2017 | $47.64M | Jun 26, 2019 |
| FY2018 | Apr 30, 2016 | $50.46M | Jun 27, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | ($1.32M) | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $15.29M | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | $11.40M | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | ($9.62M) | Jun 27, 2024 |
| FY2023 | Apr 30, 2021 | $86.53M | Jun 28, 2023 |
| FY2022 | Apr 30, 2020 | $25.10M | Jun 29, 2022 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $22.82M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $22.98M | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | $14.87M | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | $22.29M | Jun 27, 2024 |
| FY2023 | Apr 30, 2021 | $11.26M | Jun 28, 2023 |
| FY2022 | Apr 30, 2020 | $11.22M | Jun 29, 2022 |
| FY2020 | Apr 30, 2019 | $8.90M | Jun 29, 2021 |
| FY2019 | Apr 30, 2018 | $9.56M | Jun 24, 2020 |
| FY2019 | Apr 30, 2017 | $9.02M | Jun 26, 2019 |
| FY2018 | Apr 30, 2016 | $6.12M | Jun 27, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $1.12B | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $1.02B | Jun 25, 2025 |
| FY2024 | Apr 30, 2023 | $824.58M | Jun 27, 2024 |
| FY2023 | Apr 30, 2022 | $914.20M | Jun 28, 2023 |
| FY2022 | Apr 30, 2021 | $928.57M | Jun 29, 2022 |
| FY2020 | Apr 30, 2020 | $584.95M | Jun 29, 2021 |
| FY2019 | Apr 30, 2019 | $508.84M | Jun 24, 2020 |
| FY2019 | Apr 30, 2018 | $473.42M | Jun 26, 2019 |
| FY2018 | Apr 30, 2017 | $432.50M | Jun 27, 2018 |
| FY2017 | Apr 30, 2016 | $410.66M | Jun 28, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Apr 30, 2023 | $550.97M | Jun 28, 2023 |
| FY2023 | Apr 30, 2022 | $607.97M | Jun 28, 2023 |
| FY2022 | Apr 30, 2021 | $612.09M | Jun 29, 2022 |
| FY2020 | Apr 30, 2020 | $509.90M | Jun 29, 2021 |
| FY2019 | Apr 30, 2019 | $462.57M | Jun 24, 2020 |
| FY2019 | Apr 30, 2018 | $409.03M | Jun 26, 2019 |
| FY2018 | Apr 30, 2017 | $381.95M | Jun 27, 2018 |
| FY2017 | Apr 30, 2016 | $361.53M | Jun 28, 2017 |
| FY2017 | Apr 30, 2015 | $348.91M | Jun 28, 2017 |
| FY2017 | Apr 30, 2014 | $342.47M | Jun 28, 2017 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $256.78M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $275.65M | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | $180.80M | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | $334.35M | Jun 27, 2024 |
| FY2023 | Apr 30, 2021 | $314.21M | Jun 28, 2023 |
| FY2022 | Apr 30, 2020 | $6.34M | Jun 29, 2022 |
| FY2017 | Apr 30, 2017 | $122.0K | Jun 28, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $274.31M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $230.69M | Jun 25, 2025 |
| FY2024 | Apr 30, 2023 | $171.02M | Jun 27, 2024 |
| FY2023 | Apr 30, 2022 | $347.23M | Jun 28, 2023 |
| FY2022 | Apr 30, 2021 | $351.42M | Jun 29, 2022 |
| FY2020 | Apr 30, 2020 | $328.09M | Jun 29, 2021 |
| FY2019 | Apr 30, 2019 | $286.35M | Jun 24, 2020 |
| FY2019 | Apr 30, 2018 | $238.91M | Jun 26, 2019 |
| FY2018 | Apr 30, 2017 | $219.93M | Jun 27, 2018 |
| FY2017 | Apr 30, 2016 | $207.45M | Jun 28, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $40.86M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | $73.30M | Jun 25, 2025 |
| FY2024 | Apr 30, 2023 | $132.86M | Jun 27, 2024 |
| FY2023 | Apr 30, 2022 | $77.23M | Jun 28, 2023 |
| FY2022 | Apr 30, 2021 | $148.74M | Jun 29, 2022 |
| FY2020 | Apr 30, 2020 | $255.14M | Jun 29, 2021 |
| FY2019 | Apr 30, 2019 | $172.71M | Jun 24, 2020 |
| FY2019 | Apr 30, 2018 | $143.52M | Jun 26, 2019 |
| FY2018 | Apr 30, 2017 | $79.90M | Jun 27, 2018 |
| FY2018 | Apr 30, 2016 | $124.29M | Jun 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | $30.00M | Jun 25, 2025 |
| FY2024 | Apr 30, 2024 | $28.00M | Jun 27, 2024 |
| FY2023 | Apr 30, 2023 | $135.00M | Jun 28, 2023 |
| FY2022 | Apr 30, 2022 | $190.00M | Jun 29, 2022 |
| FY2020 | Apr 30, 2021 | $200.00M | Jun 29, 2021 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 1 | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | 2 | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | (7) | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | 0 | Jun 27, 2024 |
| FY2023 | Apr 30, 2021 | 0 | Jun 28, 2023 |
| FY2022 | Apr 30, 2020 | 1 | Jun 29, 2022 |
| FY2020 | Apr 30, 2019 | 2 | Jun 29, 2021 |
| FY2019 | Apr 30, 2018 | 0 | Jun 24, 2020 |
| FY2017 | Apr 30, 2017 | 1 | Jun 28, 2017 |
| FY2017 | Jan 28, 2017 | 0 | Jun 28, 2017 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 1 | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | 2 | Jun 25, 2025 |
| FY2025 | Apr 30, 2023 | (7) | Jun 25, 2025 |
| FY2024 | Apr 30, 2022 | 0 | Jun 27, 2024 |
| FY2023 | Apr 30, 2021 | 0 | Jun 28, 2023 |
| FY2022 | Apr 30, 2020 | 1 | Jun 29, 2022 |
| FY2020 | Apr 30, 2019 | 1 | Jun 29, 2021 |
| FY2019 | Apr 30, 2018 | 0 | Jun 24, 2020 |
| FY2017 | Apr 30, 2017 | 1 | Jun 28, 2017 |
| FY2017 | Jan 28, 2017 | 0 | Jun 28, 2017 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Apr 30, 2025 | 28.27M | Jun 25, 2025 |
| FY2025 | Apr 30, 2024 | 28.13M | Jun 25, 2025 |
| FY2024 | Apr 30, 2023 | 26.22M | Jun 27, 2024 |
| FY2023 | Apr 30, 2022 | 24.95M | Jun 28, 2023 |
| FY2022 | Apr 30, 2021 | 24.78M | Jun 29, 2022 |
| FY2020 | Apr 30, 2020 | 24.06M | Jun 29, 2021 |
| FY2019 | Apr 30, 2019 | 23.95M | Jun 24, 2020 |
| FY2019 | Apr 30, 2018 | 23.91M | Jun 26, 2019 |
| FY2018 | Apr 30, 2017 | 23.63M | Jun 27, 2018 |
| FY2017 | Apr 30, 2016 | 23.36M | Jun 28, 2017 |